Outcomes

The Outcomes Dashboard will provide a high-level view of MetaFlow’s real-world evidence as longitudinal data becomes available. Future reporting will include, as applicable, participant enrollment, active participation, completion rates, protocol adherence, reassessment milestones, CKM outcome signals, MSK functional changes, safety events, protocol adjustments, and escalation activity.

Outcome reporting will begin after sufficient ACCESS participation and follow-up data are available.

MetaFlow’s CKM outcomes will focus on Cardio-Kidney-Metabolic health patterns, including blood glucose, blood pressure, lipid abnormalities, fatty liver, atherosclerotic risk, kidney-related markers, and related metabolic risk indicators where available. Future CKM reporting will be organized by baseline status, reassessment timepoint, completion status, marker movement, normalization signals, reversal trajectory where applicable, and safety context.

CKM outcomes will be reported only when sufficient longitudinal data has been collected and reviewed.

MetaFlow’s MSK outcomes will focus on chronic musculoskeletal pain, physical function, mobility, functional limitation, daily activity, and quality of life. Future MSK reporting will include patient-reported outcomes, functional tracking, reassessment milestones, adherence, tolerance, and protocol adjustment patterns where available.

MSK outcomes will be reported as structured follow-up data becomes available through home execution and clinical review.

Safety is part of MetaFlow’s outcomes framework. MetaFlow will report safety-related information including adverse events, serious adverse events where applicable, red-flag escalations, protocol pauses, protocol discontinuations, referrals back to primary care or specialist care, urgent care or emergency care redirections, and exclusions due to high-risk status.

Safety reporting will be updated as the ACCESS implementation progresses and sufficient clinical governance data becomes available.

MetaFlow outcomes are designed to be reported through a longitudinal real-world evidence framework. The methodology includes structured intake, baseline clinical review, physician-supervised protocol review, home-execution tracking, symptom and tolerance monitoring, periodic reassessment, objective clinical markers where available, safety review, protocol versioning, and documented clinical rationale.

Outcomes will be organized by domain, timepoint, completion status, adherence, safety events, and protocol version. Missing or incomplete data will be handled transparently in future reporting.

Where clinically appropriate and available, MetaFlow may provide supplemental structural evidence to support longitudinal outcome interpretation. This may include de-identified imaging summaries, ultrasound follow-up, vascular structure observations, fatty liver imaging follow-up, kidney-related structural or functional context, and clinician-reviewed case-level evidence.

Supplemental materials will be added only when they are appropriately reviewed, de-identified, and relevant to understanding the patient’s trajectory over time.